Recurrence of hepatocellular carcinoma: Importance of mRECIST response to chemoembolization and tumor size

American Journal of Transplantation

Volumn 14, Issue 6, 2014, Pages 1383-1390

  Kim, D J ^a   Clark, P J ^b   Heimbach, J ^c   Rosen, C ^c   Sanchez, W ^c   Watt, K ^c   Charlton, M R ^d  

^a Hallym University Medical Center   (South Korea)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c MAYO CLINIC   (United States)

^d INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Chemoembolization; hepatocellular carcinoma; liver transplantation; recurrence

Indexed keywords

DOXORUBICIN; MITOMYCIN;

ADULT; ARTICLE; CANCER RECURRENCE; CHEMOEMBOLIZATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME; AGED; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RECURRENT DISEASE;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE;

EID: 84901281242     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12684     Document Type: Article

References (18)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis (see comments). N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
2. Llovet JM, Fuster J, Bruix J., Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-1440.
3. Stockland AH, Walser EM, Paz-Fumagalli R, McKinney JM, May GR., Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: Influence of emergent versus elective procedures on patient survival and tumor recurrence rate. Cardiovasc Intervent Radiol 2007; 30: 888-893. (Pubitemid 47497868)
4. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267. (Pubitemid 44194595)
5. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279. (Pubitemid 46351654)
6. Vitale A, D'Amico F, Frigo A, et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17: 2290-2302.
7. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539. (Pubitemid 34258353)
8. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775. (Pubitemid 40975578)
9. Lencioni R, Llovet JM., Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
10. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
11. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
12. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
13. Ioannou GN, Perkins JD, Carithers RL Jr., Liver transplantation for hepatocellular carcinoma: Impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351. (Pubitemid 351615357)
14. Klintmalm GB., Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479-490. (Pubitemid 30194392)
15. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403. (Pubitemid 32496976)
16. Bargellini I, Vignali C, Cioni R, et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria-Selection parameter for liver transplantation. Radiology 2010; 255: 289-300.
17. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: A model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.e3.
18. Bruix J, Sherman M., Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)